Europe develops to a High tech Market
PROCESS: Looking back to the investments in Europe of the last 2-3 years, there seems to be a focus on biotechnology in Western Europe — also due to Roche. Exception is the new solid dosage production of Novartis in Stein. Is there a tendency that Europe develops to a high tech market in the pharma industry?
Berg: Yes, the market for high tech is clearly in Western Europe. This comprises not only biotech but also other areas, particularly the high containment sector or sterile filling areas where advanced technology know-how is requested. I think that in the long term the pharma industry will produce locally for local markets including country-specific product brands in the suitable price level.
PROCESS: Is there something like a European technology boarder, meaning high tech and parenterals in Western Europe and solid dosage production rather in Eastern Europe?
Berg: There are certainly generic manufacturers who concentrate on Eastern Europe, but I would not say that this is a trend in general. Also in the solid dosage production, advanced technology is applied like in the containment or continuous production area.
PROCESS: Looking at the numbers of newly approved drugs or the active pharmaceutical ingredients in the pipeline, can biotechnology be seen without a doubt internationally as a growing market? Does this also count for NNE Pharmaplan in Central Europe?
Berg: Yes, of course. This also applies for NNE Pharmaplan. We recognise this in all our locations in Central Europe. But also investments in solid dosage production and packaging facilities as well as laboratories keep us just as busy.
This article is protected by copyright. You want to use it for your own purpose? Contact us via: support.vogel.de/ (ID: 43358484 / Pharma & Food)